Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 8/20 | 1.00 |
| ▸ | MEN1 | O00255 | 6/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 6/20 | 1.00 |
| ▸ | RAB9A | P51151 | 5/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 1.00 |
| ▸ | NPC1 | O15118 | 4/20 | 0.72 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.68 |
| ▸ | HTT | P42858 | 2/20 | 0.68 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 4/20 | 0.63 |
| ▸ | MAPT | P10636 | 3/20 | 0.63 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | PKM | P14618 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | GMNN | O75496 | 1/20 | 0.56 |
| ▸ | TTR | P02766 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL479877 | 0.87 | DHODH (1.00) | DHODHMEN1KMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL4686279 | 0.86 | DHODH (0.76) | DHODHMEN1KMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL28824933 | 0.86 | RAB9A (0.76) | DHODHMEN1KMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL29898323 | 0.86 | RAB9A (0.76) | DHODHMEN1KMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL16616388 | 0.86 | RAB9A (0.76) | DHODHMEN1KMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL3807873 | 0.84 | DHODH (0.77) | DHODHMEN1KMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL15636491 | 0.84 | DHODH (1.00) | DHODHMEN1KMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL12431830 | 0.84 | DHODH (0.77) | DHODHMEN1KMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL28534915 | 0.84 | DHODH (0.81) | DHODHMEN1KMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL4905983 | 0.84 | DHODH (0.72) | DHODHMEN1KMT2ARAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116574053-A | RIPK1 kinase target inhibitor and medical application thereof | 中国药科大学 | 2023-08-11 | — | — | CN | disclosed |
| CN-114989079-B | RIPK1 kinase target inhibitor and medical application thereof | 中国药科大学 | 2023-06-23 | — | — | CN | disclosed |
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| CN-114989079-A | RIPK1 kinase target inhibitor and medical application thereof | 中国药科大学 | 2022-09-02 | — | — | CN | disclosed |
| US-20220016106-A1 | COMPOUNDS AND METHODS USEFUL FOR TREATING OR PREVENTING HEMATOLOGICAL CANCERS | THE BROAD INSTITUTE, INC. (US) | 2022-01-20 | — | — | US | disclosed |
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| EP-3344243-B1 | COMPOUNDS AND METHODS USEFUL FOR TREATING OR PREVENTING HEMATOLOGICAL CANCERS | BROAD INST INC (US) | 2020-12-09 | — | — | EP | disclosed |
| US-20190192691-A1 | REGULATED BIOCIRCUIT SYSTEMS | OBSIDIAN THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| US-9029553-B2 | 2-anilino nicotinyl linked 2-amino benzothiazole conjugates and process for the preparation thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2015-05-12 | — | — | US | disclosed |
| EP-2675802-A1 | 2-ANILINO NICOTINYL LINKED 2-AMINO BENZOTHIAZOLE CONJUGATES AND PROCESS FOR THE PREPARATION THEREOF | Council of Scientific & Industrial Research (IN) | 2013-12-25 | — | — | EP | disclosed |
| US-20130324734-A1 | 2-ANILINO NICOTINYL LINKED 2-AMINO BENZOTHIAZOLE CONJUGATES AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2013-12-05 | — | — | US | disclosed |
| WO-2012111016-A1 | 2-ANILINO NICOTINYL LINKED 2-AMINO BENZOTHIAZOLE CONJUGATES AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2012-08-23 | — | — | WO | disclosed |
| US-5219953-A | High stiffness molding materials | ENIRICERCHE S.P.A. (IT) | 1993-06-15 | — | — | US | disclosed |
| US-5182289-A | Pyrrolo 2,3-b!Pyridin-2-one Derivatives | SCHERING CORPORATION (US) | 1993-01-26 | — | — | US | disclosed |
| US-5070155-A | AMINOBENZOIC OR HYDROXYBENZOIC ACID AND DIACID OR BIPHENOL | ENIRICERCHE, S.P.A. (IT) | 1991-12-03 | — | — | US | disclosed |
| EP-0419561-A1 | HETEROBICYCLIC COMPOUNDS HAVING ANTIINFLAMMATORY ACTIVITY | SCHERING CORPORATION (US) | 1991-04-03 | — | — | EP | disclosed |
| WO-1989012637-A1 | HETEROBICYCLIC COMPOUNDS HAVING ANTIINFLAMMATORY ACTIVITY | SCHERING CORPORATION (US) | 1989-12-28 | — | — | WO | disclosed |
| EP-0347698-A1 | Heterobicyclic compounds having antiinflammatory activity | SCHERING CORPORATION (US) | 1989-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130324734-A1 | 2-ANILINO NICOTINYL LINKED 2-AMINO BENZOTHIAZOLE CONJUGATES AND PROCESS FOR THE PREPARATION THEREOF | CASP2, NAPRT, NME2 | DHODH 680/4885MEN1 3039/4885KMT2A 1070/4885 |
| US-20220016106-A1 | COMPOUNDS AND METHODS USEFUL FOR TREATING OR PREVENTING HEMATOLOGICAL CANCERS | DHODH, MCL1, DHX15 | DHODH 1/4885MEN1 1995/4885KMT2A 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.